Responder Analysis of the Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

BACKGROUND: Men with prostate cancer are at risk of experiencing accelerated bone loss and fractures as a result of androgen deprivation therapy (ADT). OBJECTIVE: We evaluated the effects of denosumab, a fully human monoclonal antibody against RANKL, on preservation of BMD at 3 key skeletal sites (l...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Egerdie, Blair, Saad, Fred, Smith, Matthew R, Tammela, Teuvo LJ, Heracek, Jiri, Sieber, Paul, Ke, Chunlei, Leder, Benjamin, Dansey, Roger, Goessl, Carsten
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3671885/
https://ncbi.nlm.nih.gov/pubmed/22641239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2012.18
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC3671885/
https://ncbi.nlm.nih.gov/pubmed/22641239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2012.18

Podobné jednotky